Enhanced T cell function in a mouse model of human glycosylation

Journal of Immunology

Volumn 191, Issue 1, 2013, Pages 228-237

  Buchlis, George ^a,b   Odorizzi, Pamela ^a   Soto, Paula C ^c   Pierce, Oliver M T ^c   Hui, Daniel J ^b   Jordan, Martha S ^a   Varki, Ajt ^c   Wherry, E John ^a   High, Katherine A ^a,b,d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACYLNEURAMINATE CYTIDYLYLTRANSFERASE;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GLYCOSYLATION; HUMAN; HUMAN CELL; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TRANSGENE; VIRUS INFECTION; WILD TYPE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; DEPENDOVIRUS; GLYCOSYLATION; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MIXED FUNCTION OXYGENASES; T-LYMPHOCYTE SUBSETS; UP-REGULATION;

EID: 84879639480     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1202905     Document Type: Article

References (48)

1. Varki, A., and J. B. Lowe. 2009. Biological roles of glycans. In Essentials of Glycobiology, 2nd Ed. A. Varki, R. D. Cummings, J. D. Esko, H. H. Freeze, P. Stanley, C. R. Bertozzi, G. W. Hart, and M. E. Etzler, eds. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
2. Chou, H. H., H. Takematsu, S. Diaz, J. Iber, E. Nickerson, K. L. Wright, E. A. Muchmore, D. L. Nelson, S. T. Warren, and A. Varki. 1998. A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc. Natl. Acad. Sci. USA 95: 11751-11756.
3. Irie, A., S. Koyama, Y. Kozutsumi, T. Kawasaki, and A. Suzuki. 1998. The molecular basis for the absence of N-glycolylneuraminic acid in humans. J. Biol. Chem. 273: 15866-15871. (Pubitemid 28298210)
4. Brinkman-Van der Linden, E. C., E. R. Sjoberg, L. R. Juneja, P. R. Crocker, N. Varki, and A. Varki. 2000. Loss of N-glycolylneuraminic acid in human evolution. Implications for sialic acid recognition by siglecs. J. Biol. Chem. 275: 8633-8640.
5. Tangvoranuntakul, P., P. Gagneux, S. Diaz, M. Bardor, N. Varki, A. Varki, and E. Muchmore. 2003. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc. Natl. Acad. Sci. USA 100: 12045-12050. (Pubitemid 37271512)
6. Varki, A. 2010. Colloquium paper: uniquely human evolution of sialic acid genetics and biology. Proc. Natl. Acad. Sci. USA 107(Suppl. 2): 8939-8946.
7. Varki, N. M., E. Strobert, E. J. Dick, Jr., K. Benirschke, and A. Varki. 2011. Biomedical differences between human and nonhuman hominids: potential roles for uniquely human aspects of sialic acid biology. Annu. Rev. Pathol. 6: 365-393.
8. Crocker, P. R., J. C. Paulson, and A. Varki. 2007. Siglecs and their roles in the immune system. Nat. Rev. Immunol. 7: 255-266. (Pubitemid 46480955)
9. Varki, A., and P. R. Crocker. 2009. I-type lectins. In Essentials of Glycobiology, 2nd Ed. A. Varki, R. D. Cummings, J. D. Esko, H. H. Freeze, P. Stanley, C. R. Bertozzi, G. W. Hart, and M. E. Etzler, eds. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
10. Ravetch, J. V., and L. L. Lanier. 2000. Immune inhibitory receptors. Science 290: 84-89.
11. Collins, B. E., O. Blixt, A. R. DeSieno, N. Bovin, J. D. Marth, and J. C. Paulson. 2004. Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact. Proc. Natl. Acad. Sci. USA 101: 6104-6109. (Pubitemid 38520535)
12. Doody, G. M., L. B. Justement, C. C. Delibrias, R. J. Matthews, J. Lin, M. L. Thomas, and D. T. Fearon. 1995. A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science 269: 242-244.
13. Taylor, V. C., C. D. Buckley, M. Douglas, A. J. Cody, D. L. Simmons, and S. D. Freeman. 1999. The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J. Biol. Chem. 274: 11505-11512.
14. Vitale, C., C. Romagnani, M. Falco, M. Ponte, M. Vitale, A. Moretta, A. Bacigalupo, L. Moretta, and M. C. Mingari. 1999. Engagement of p75/ AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. Proc. Natl. Acad. Sci. USA 96: 15091-15096. (Pubitemid 30019770)
15. Ikehara, Y., S. K. Ikehara, and J. C. Paulson. 2004. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. J. Biol. Chem. 279: 43117-43125. (Pubitemid 39372207)
16. Hoffmann, A., S. Kerr, J. Jellusova, J. Zhang, F. Weisel, U. Wellmann, T. H. Winkler, B. Kneitz, P. R. Crocker, and L. Nitschke. 2007. Siglec-G is a B1 cell-inhibitory receptor that controls expansion and calcium signaling of the B1 cell population. Nat. Immunol. 8: 695-704. (Pubitemid 46965345)
17. Yu, Z., M. Maoui, L. Wu, D. Banville, and S. Shen. 2001. mSiglec-E, a novel mouse CD33-related siglec (sialic acid-binding immunoglobulin-like lectin) that recruits Src homology 2 (SH2)-domain-containing protein tyrosine phosphatases SHP-1 and SHP-2. Biochem. J. 353: 483-492. (Pubitemid 32158316)
18. Zhang, M., T. Angata, J. Y. Cho, M. Miller, D. H. Broide, and A. Varki. 2007. Defining the in vivo function of Siglec-F, a CD33-related Siglec expressed on mouse eosinophils. Blood 109: 4280-4287. (Pubitemid 46743394)
19. Nguyen, D. H., N. Hurtado-Ziola, P. Gagneux, and A. Varki. 2006. Loss of Siglec expression on T lymphocytes during human evolution. Proc. Natl. Acad. Sci. USA 103: 7765-7770.
20. Soto, P. C., L. L. Stein, N. Hurtado-Ziola, S. M. Hedrick, and A. Varki. 2010. Relative over-reactivity of human versus chimpanzee lymphocytes: implications for the human diseases associated with immune activation. J. Immunol. 184: 4185-4195.
21. Manno, C. S., G. F. Pierce, V. R. Arruda, B. Glader, M. Ragni, J. J. Rasko, M. C. Ozelo, K. Hoots, P. Blatt, B. Konkle, et al. 2006. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. [Published erratum appears in 2006 Nat. Med. 12: 592.] Nat. Med. 12: 342-347. (Pubitemid 43355084)
22. Nathwani, A. C., E. G. D. Tuddenham, S. Rangarajan, C. Rosales, J. McIntosh, D. C. Linch, P. Chowdary, A. Riddell, A. J. Pie, C. Harrington, et al. 2011. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N. Engl. J. Med. 365: 2357-2365.
23. Mingozzi, F., M. V. Maus, D. J. Hui, D. E. Sabatino, S. L. Murphy, J. E. J. Rasko, M. V. Ragni, C. S. Manno, J. Sommer, H. Jiang, et al. 2007. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13: 419-422.
24. Li, H., S. L. Murphy, W. Giles-Davis, S. Edmonson, Z. Xiang, Y. Li, M. O. Lasaro, K. A. High, and H. C. Ertl. 2007. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol. Ther. 15: 792-800. (Pubitemid 46432000)
25. Wang, L., J. Figueredo, R. Calcedo, J. Lin, and J. M. Wilson. 2007. Crosspresentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum. Gene Ther. 18: 185-194. (Pubitemid 46626458)
26. Li, C., M. Hirsch, N. DiPrimio, A. Asokan, K. Goudy, R. Tisch, and R. J. Samulski. 2009. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo. J. Virol. 83: 6817-6824.
27. Hedlund, M., P. Tangvoranuntakul, H. Takematsu, J. M. Long, G. D. Housley, Y. Kozutsumi, A. Suzuki, A. Wynshaw-Boris, A. F. Ryan, R. L. Gallo, et al. 2007. N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution. Mol. Cell. Biol. 27: 4340-4346. (Pubitemid 46906558)
28. Naito, Y., H. Takematsu, S. Koyama, S. Miyake, H. Yamamoto, R. Fujinawa, M. Sugai, Y. Okuno, G. Tsujimoto, T. Yamaji, et al. 2007. Germinal center marker GL7 probes activation-dependent repression of N-glycolylneuraminic acid, a sialic acid species involved in the negative modulation of B-cell activation. Mol. Cell. Biol. 27: 3008-3022. (Pubitemid 46581314)
29. Chandrasekharan, K., J. H. Yoon, Y. Xu, S. deVries, M. Camboni, P. M. L. Janssen, A. Varki, and P. T. Martin. 2010. A human-specific deletion in mouse Cmah increases disease severity in the mdx model of duchenne muscular dystrophy. Sci. Transl. Med. 2: 42ra54.
30. Redelinghuys, P., A. Antonopoulos, Y. Liu, M. A. Campanero-Rhodes, E. McKenzie, S. M. Haslam, A. Dell, T. Feizi, and P. R. Crocker. 2011. Early murine T-lymphocyte activation is accompanied by a switch from N-Glycolyl- to N-acetyl-neuraminic acid and generation of ligands for siglec-E. J. Biol. Chem. 286: 34522-34532.
31. Pearce, O. M. T., and A. Varki. 2010. Chemo-enzymatic synthesis of the carbohydrate antigen N-glycolylneuraminic acid from glucose. Carbohydr. Res. 345: 1225-1229.
32. Sabatino, D. E., F. Mingozzi, D. J. Hui, H. Chen, P. Colosi, H. C. J. Ertl, and K. A. High. 2005. Identification of mouse AAV capsid-specific CD8+ T cell epitopes. Mol. Ther. 12: 1023-1033. (Pubitemid 41723036)
33. Ahmed, R., A. Salmi, L. D. Butler, J. M. Chiller, and M. B. Oldstone. 1984. Selection of genetic variants of lymphocytic choriomeningitis virus in spleens of persistently infected mice. Role in suppression of cytotoxic T lymphocyte response and viral persistence. J. Exp. Med. 160: 521-540. (Pubitemid 14052514)
34. Bardor, M., D. H. Nguyen, S. Diaz, and A. Varki. 2005. Mechanism of uptake and incorporation of the non-human sialic acid N-glycolylneuraminic acid into human cells. J. Biol. Chem. 280: 4228-4237. (Pubitemid 40288589)
35. Varki, A., and P. Gagneux. 2009. Human-specific evolution of sialic acid targets: explaining the malignant malaria mystery? Proc. Natl. Acad. Sci. USA 106: 14739-14740.
36. Sathish, J. G., J. Walters, J. C. Luo, K. G. Johnson, F. G. Leroy, P. Brennan, K. P. Kim, S. P. Gygi, B. G. Neel, and R. J. Matthews. 2004. CD22 is a functional ligand for SH2 domain-containing protein-tyrosine phosphatase-1 in primary T cells. J. Biol. Chem. 279: 47783-47791. (Pubitemid 39540927)
37. Sarkar, S., V. Kalia, W. N. Haining, B. T. Konieczny, S. Subramaniam, and R. Ahmed. 2008. Functional and genomic profiling of effector CD8 T cell subsets with distinct memory fates. J. Exp. Med. 205: 625-640. (Pubitemid 351439309)
38. Jung, Y. W., R. L. Rutishauser, N. S. Joshi, A. M. Haberman, and S. M. Kaech. 2010. Differential localization of effector and memory CD8 T cell subsets in lymphoid organs during acute viral infection. J. Immunol. 185: 5315-5325.
39. Kaech, S. M., and E. J. Wherry. 2007. Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection. Immunity 27: 393-405. (Pubitemid 47418674)
40. Wherry, E. J., and R. Ahmed. 2004. Memory CD8 T-cell differentiation during viral infection. J. Virol. 78: 5535-5545. (Pubitemid 38661640)
41. Jameson, S. C., and D. Masopust. 2009. Diversity in T cell memory: an embarrassment of riches. Immunity 31: 859-871.
42. Sarkar, S., V. Teichgrä ber, V. Kalia, A. Polley, D. Masopust, L. E. Harrington, R. Ahmed, and E. J. Wherry. 2007. Strength of stimulus and clonal competition impact the rate of memory CD8 T cell differentiation. J. Immunol. 179: 6704-6714.
43. Li, H., S.-W. Lin, W. Giles-Davis, Y. Li, D. Zhou, Z. Q. Xiang, K. A. High, and H. C. J. Ertl. 2009. A preclinical animal model to assess the effect of preexisting immunity on AAV-mediated gene transfer. Mol. Ther. 17: 1215-1224.
44. Mingozzi, F., and K. A. High. 2011. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet. 12: 341-355.
45. Li, H., M. O. Lasaro, B. Jia, S.-W. Lin, L. H. Haut, K. A. High, and H. C. J. Ertl. 2011. Capsid-specific T-cell responses to natural infections with adenoassociated viruses in humans differ from those of nonhuman primates. Mol. Ther. 19: 2021-2030.
46. Mingozzi, F., N. C. Hasbrouck, E. Basner-Tschakarjan, S. A. Edmonson, D. J. Hui, D. E. Sabatino, S. Zhou, J. F. Wright, H. Jiang, G. F. Pierce, et al. 2007. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 110: 2334-2341. (Pubitemid 47523153)
47. Nathwani, A. C., J. T. Gray, J. McIntosh, C. Y. C. Ng, J. Zhou, Y. Spence, M. Cochrane, E. Gray, E. G. D. Tuddenham, and A. M. Davidoff. 2007. Safe and efficient transduction of the liver after peripheral vein infusion of selfcomplementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates. Blood 109: 1414-1421. (Pubitemid 46239572)
48. Nathwani, A. C., C. Rosales, J. McIntosh, G. Rastegarlari, D. Nathwani, D. Raj, S. Nawathe, S. N. Waddington, R. Bronson, S. Jackson, et al. 2011. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol. Ther. 19: 876-885.